So, it was a healthy start to the year, M&A-wise, for one of the worst-performing sectors of the S&P 500® in 2024. The Health ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX – Research Report), Amgen (AMGN – ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.